Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Fund Letter | Jeffrey KolitchBaron Real Estate Income Fund | The Macerich Company $MAC• NYSE | Equity Real Estate Investment Trusts (REITs)Equity Real Estate Investment Trusts (REITs) | Baron Real Estate Fund - MAC The Macerich Company, a high-quality retail mall REIT, contributed positively to performance in the second quarter, driven by management's continued strong execution. Key highlights included... | BULL | View Pitch → |
| Aug 21, 2026 | Fund Letter | Yaron Naymark1 Main Capital | DIAMEDICA THERAPEUTICS INC $DMAC• NASDAQ | -- | Long DMAC (DIAMEDICA THERAPEUTICS INC) The Fund holds an opportunistic position in DiaMedica Therapeutics (DMAC), a clinical-stage biotechnology company that has developed DM199, a recombinant (synthetic) form of the naturally occurring tissue kallikrein-1 (KLK1) protein — a critical molecular trigger for blood-vessel dilation. Stroke Indication ($10... | BULL | View Pitch → |
| Aug 21, 2026 | Fund Letter | Scott KlarquistSeven Corners Capital Management, LLC | Merrimack Pharmaceuticals $MACK• NASDAQ | -- | Long MACK (Merrimack Pharmaceuticals) MACK, which was up 17% during 2023, is a classic uncorrelated "discount to the sum-of-the-parts" play. It can be... | BULL | View Pitch → |
| Aug 1, 2026 | Fund Letter | Yaron Naymark1 Main Capital | DIAMEDICA THERAPEUTICS INC $DMAC• NASDAQ | -- | 1 Main Capital - DMAC The Fund holds an opportunistic position in DiaMedica Therapeutics (DMAC), a clinical-stage biotechnology company that has developed DM199, a recombinant (synthetic) form of the naturally occurring tissue kallikrein-1 (KLK1) protein — a critical molecular trigger for blood-vessel dilation. Naturally derived KLK1... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.